Literature DB >> 19916022

A new staging system is more discriminant than conventional staging systems for unresectable hepatocellular carcinoma.

Bai-Hong Zhang1, Xiang-Hui Wang, Hong-Yun Yue, Chang-Quan Ling.   

Abstract

BACKGROUND: Prediction of the life expectancy of a patient with unresectable hepatocellular carcinoma (HCC) remains difficult. The aims of the study were to construct a new staging scheme for patients with unresectable HCC and to compare the discriminatory ability of the staging scheme with the Okuda and CLIP score and TNM staging system in a cohort of patients with unresectable HCC.
METHODS: A retrospective analysis of unresectable HCC cases from 1999 to 2003 was performed. The Cox model was used for multivariate analyses. The final model was derived from 10 randomly chosen training samples and the prognostic validity of the new staging scheme was assessed on the corresponding testing samples. Moreover, 54 cases with unresectable HCC were enrolled and prospectively followed up. The new staging, named the China integrated score (CIS), Okuda, TNM and CLIP systems were determined for each case. Comparisons of the survival rate between each stage were performed to evaluate their discriminatory ability.
RESULTS: A simple scoring system was constructed, assigning linear scores (0/1/2) to the three covariates (TNM, alpha-fetoprotein and Child-Pugh) of the final model. The CIS system was more discriminant than the Okuda or TNM staging system, as confirmed by the Kaplan-Meier comparison of survival curves and by the Cox's regression analysis, with a median survival rate of 9.0, 2.3, 2.1 and 0.6 months in patients with CIS 2, 3, 4 and 5, respectively. The CIS system was performed as well as the CLIP score.
CONCLUSION: The new staging system, accounting for both liver function and tumor characteristics, can accurately identify patients with different prognoses, particularly in the advanced phases of HCC. It should be useful as the only tool that can be applied for patients with unresectable HCC.

Entities:  

Mesh:

Year:  2009        PMID: 19916022     DOI: 10.1007/s00432-009-0722-1

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  12 in total

1.  Cancer of the Liver Italian Program (CLIP) score for staging hepatocellular carcinoma.

Authors:  Bruno Daniele; Mena Annunziata; Emiddio Barletta; Vincenza Tinessa; Massimo Di Maio
Journal:  Hepatol Res       Date:  2007-09       Impact factor: 4.288

2.  Comparison of 7 staging systems for patients with hepatocellular carcinoma undergoing transarterial chemoembolization.

Authors:  Yun Ku Cho; Jin Wook Chung; Jae Kyun Kim; Yong Sik Ahn; Mi Young Kim; Yoon Ok Park; Wan Tae Kim; Jong Hoon Byun
Journal:  Cancer       Date:  2008-01-15       Impact factor: 6.860

3.  A new prognostic staging system for hepatocellular carcinoma: value of the biomarker combined Japan integrated staging score.

Authors:  Satoshi Kitai; Masatoshi Kudo; Yasunori Minami; Kazuomi Ueshima; Hobyung Chung; Satoru Hagiwara; Tatsuo Inoue; Emi Ishikawa; Shunsuke Takahashi; Yutaka Asakuma; Seiji Haji; Yukio Osaki; Hiroko Oka; Toshihito Seki; Hiroshi Kasugai; Yo Sasaki; Takashi Matsunaga
Journal:  Intervirology       Date:  2008-06-10       Impact factor: 1.763

4.  How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system.

Authors:  F Farinati; M Rinaldi; S Gianni; R Naccarato
Journal:  Cancer       Date:  2000-12-01       Impact factor: 6.860

Review 5.  Prognosis of hepatocellular carcinoma.

Authors:  Josep M Llovet; Josep Fuster; Jordi Bruix
Journal:  Hepatogastroenterology       Date:  2002 Jan-Feb

6.  A new prognostic score system in patients with advanced hepatocellular carcinoma not amendable to locoregional therapy: implication for patient selection in systemic therapy trials.

Authors:  Thomas Yau; Tzy Jyun Yao; Pierre Chan; Kelvin Ng; Sheung Tat Fan; Ronnie T P Poon
Journal:  Cancer       Date:  2008-11-15       Impact factor: 6.860

Review 7.  Management of hepatocellular carcinoma.

Authors:  A Said; J Wells
Journal:  Minerva Med       Date:  2009-02       Impact factor: 4.806

Review 8.  Current management of hepatocellular carcinoma.

Authors:  Manuel Mendizabal; K Rajender Reddy
Journal:  Med Clin North Am       Date:  2009-07       Impact factor: 5.456

9.  A new prognostic system for hepatocellular carcinoma including recurrent cases: a study of 861 patients in a single institution.

Authors:  Takashi Toyama; Naoki Hiramatsu; Takayuki Yakushijin; Tsugiko Oze; Fumihiko Nakanishi; Masakazu Yasumaru; Kiyoshi Mochizuki; Tatsuya Kanto; Tetsuo Takehara; Akinori Kasahara; Norio Hayashi
Journal:  J Clin Gastroenterol       Date:  2008-03       Impact factor: 3.062

10.  Comprehensive analysis of the alpha-fetoprotein-specific CD8+ T cell responses in patients with hepatocellular carcinoma.

Authors:  Robert Thimme; Michaela Neagu; Tobias Boettler; Christoph Neumann-Haefelin; Nadine Kersting; Michael Geissler; Frank Makowiec; Robert Obermaier; Ulrich T Hopt; Hubert E Blum; Hans Christian Spangenberg
Journal:  Hepatology       Date:  2008-12       Impact factor: 17.425

View more
  6 in total

Review 1.  Predictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: where are we?

Authors:  Yu-Yun Shao; Chih-Hung Hsu; Ann-Lii Cheng
Journal:  Liver Cancer       Date:  2013-04       Impact factor: 11.740

Review 2.  Staging systems for hepatocellular carcinoma: Current status and future perspectives.

Authors:  Akiyoshi Kinoshita; Hiroshi Onoda; Nao Fushiya; Kazuhiko Koike; Hirokazu Nishino; Hisao Tajiri
Journal:  World J Hepatol       Date:  2015-03-27

3.  Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems.

Authors:  Y-Y Shao; L-C Lu; Z-Z Lin; C Hsu; Y-C Shen; C-H Hsu; A-L Cheng
Journal:  Br J Cancer       Date:  2012-10-11       Impact factor: 7.640

4.  Prognosis of unresectable hepatocellular carcinoma: comparison of seven staging systems (TNM, Okuda, BCLC, CLIP, CUPI, JIS, CIS) in a Chinese cohort.

Authors:  Jin-feng Zhang; Zhi-jun Shu; Chun-yi Xie; Qi Li; Xi-hong Jin; Wei Gu; Fang-jian Jiang; Chang-quan Ling
Journal:  PLoS One       Date:  2014-03-07       Impact factor: 3.240

5.  Validation and ranking of seven staging systems of hepatocellular carcinoma.

Authors:  Zhan-Hong Chen; Ying-Fen Hong; Jinxiang Lin; Xing Li; Dong-Hao Wu; Jing-Yun Wen; Jie Chen; Dan-Yun Ruan; Qu Lin; Min Dong; Li Wei; Tian-Tian Wang; Ze-Xiao Lin; Xiao-Kun Ma; Xiang-Yuan Wu; Ruihua Xu
Journal:  Oncol Lett       Date:  2017-05-22       Impact factor: 2.967

6.  Development and Validation of Artificial Neural Networks for Survival Prediction Model for Patients with Spontaneous Hepatocellular Carcinoma Rupture After Transcatheter Arterial Embolization.

Authors:  Yiwen Qiu; Tao Wang; Xianwei Yang; Shu Shen; Yi Yang; Wentao Wang
Journal:  Cancer Manag Res       Date:  2021-09-27       Impact factor: 3.989

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.